Leukotriene receptor antagonists and Churg-Strauss syndrome: Cause, trigger or merely an association?

Drug Safety

Volumn 30, Issue 10, 2007, Pages 837-843

  Keogh, Karina A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLUCOCORTICOID; LEUKOTRIENE A4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; NEUTROPHIL CYTOPLASMIC ANTIBODY; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CHURG STRAUSS SYNDROME; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHURG-STRAUSS SYNDROME; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 34748834587     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730100-00003     Document Type: Review

References (44)

1. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340 (3): 197-206
2. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399 (6738): 789-93
3. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998; 114 (1): 332-4
4. Churg J, Churg A. Zafirlukast and Churg-Strauss syndrome. JAMA 1998; 279 (24): 1949-50
5. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279 (6): 455-7
6. Wechsler ME, Drazen JM. Zafirlukast and Churg-Strauss syndrome. Chest 1999; 116 (1): 266-7
7. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117 (3): 708-13
8. Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. Thorax 1999; 54 (6): 558-60
9. Kinoshita M, Shiraishi T, Koga T, et al. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 534-5
10. Weller PF, Plaut M, Taggart V, et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108 (2): 175-83
11. Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore), 1984; 63 (2): 65-81
12. Keogh KA, Specks U. Churg-Strauss syndrome: update on clinical, laboratory and therapeutic aspects. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (1): 3-12
13. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115 (4): 284-90
14. Wardle EN. Churg-Strauss syndrome. Lancet 2003; 361 (9370): 1746
15. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78 (1): 26-37
16. Chumbley LC, Harrison Jr EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome): report and analysis of 30 cases. Mayo Clin Proc 1977; 52 (8): 477-84
17. Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM 1998; 91 (3): 219-29
18. Solans R, Bosch JA, Selva A, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40 (7): 763-71
19. Cohen A, Johnson N, Prier A, et al. Segmental myocarditis in Churg-Strauss syndrome: review of the literature apropos of a case [in French]. Rev Med Interne 1995; 16 (1): 58-62
20. Cottin V, Cordier JF. Churg-Strauss syndrome. Allergy 1999; 54 (6): 535-51
21. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47 (5): 770-9
22. Russell KA, Specks U. Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. Rheum Dis Clin North Am 2001; 27 (4): 815-32, vii
23. Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 2006; 27 (2): 148-57
24. Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43 (2): 414-9
25. Watts RA, Gonzalez-Gay MA, Lane SE, et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60 (2): 170-2
26. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53 (1): 93-9
27. Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51 (1): 92-9
28. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, et al. The epidemiology of the primary systemic vasculitides in north-west Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49 (3): 388-93
29. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999; 8 (3): 179-89
30. Harrold LR, Andrade SE, Go AS, et al. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005; 32 (6): 1076-80
31. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33 (8): 1094-100
32. DuMouchel W, Smith ET, Beasley R, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004; 26 (7): 1092-104
33. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf 2007; 16 (6): 620-6
34. Snyder L, Blanc PD, Katz PP, et al. Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma? Arch Intern Med 2004; 164 (6): 617-22
35. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294 (5548): 1871-5
36. Pedersen KE, Bochner BS, Undem BJ. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther 1997; 281 (2): 655-62
37. Partal A, Moshfeghi DM, Alcorn D. Churg-Strauss syndrome in a child: retina and optic nerve findings. Br J Ophthalmol 2004; 88 (7): 971-2
38. Lilly CM, Churg A, Lazarovich M, et al. Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol 2002; 109 (1): S1-19
39. Garcia-Marcos L, Schuster A, Perez-Yarza EG. Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf 2003; 26 (7): 483-518
40. Masi AT, Hamilos DL. Leukotriene antagonists: bystanders or causes of Churg-Strauss syndrome? Semin Arthritis Rheum 2002; 31 (4): 211-7
41. Dahlen SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006; 533 (1-3): 40-56
42. Jamaleddine G, Diab K, Tabbarah Z, et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum, 2002; 31 (4): 218-27
43. Sheffer AL, Rocklin RE, Goetzl EJ. Immunologic components of hypersensitivity reactions to cromolyn sodium. N Engl J Med 1975; 293 (24): 1220-4
44. Le Gall C, Pham S, Vignes S, et al. Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. Eur Respir J 2000; 15 (5): 978-81